Scarica l'app Stockscreener
25.31
1.57%
0.39
Dopo l'orario di chiusura:
25.55
0.24
+0.95%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$24.92
Aprire:
$24.69
Volume 24 ore:
2.30M
Relative Volume:
1.13
Capitalizzazione di mercato:
$3.03B
Reddito:
$59.61M
Utile/perdita netta:
$-262.14M
Rapporto P/E:
-6.4566
EPS:
-3.92
Flusso di cassa netto:
$-247.49M
1 W Prestazione:
+25.86%
1M Prestazione:
+34.27%
6M Prestazione:
+69.75%
1 anno Prestazione:
+204.57%
Intervallo 1D:
$24.63
$25.56
Intervallo di 1 settimana:
$19.60
$27.08
Portata 52W:
$8.29
$27.08
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Confronta ARQT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
25.31 | 3.05B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 40,000 Shares - MarketBeat
HC Wainwright Has Positive Outlook for ARQT Q4 Earnings - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Results: Arcutis Biotherapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit - simplywall.st
How high can Arcutis Biotherapeutics Inc. stock go2025 Institutional Moves & Breakout Confirmation Alerts - newser.com
What the charts say about Arcutis Biotherapeutics Inc. todayTrade Risk Report & Detailed Earnings Play Alerts - newser.com
Is Arcutis Biotherapeutics Inc. stock dividend yield sustainableQuarterly Trade Summary & Fast Moving Stock Watchlists - newser.com
Is Arcutis Biotherapeutics Inc. stock poised for growthJuly 2025 Short Interest & AI Enhanced Trade Execution Alerts - newser.com
Is Arcutis Biotherapeutics Inc. stock safe for conservative investors2025 Breakouts & Breakdowns & Technical Confirmation Alerts - newser.com
Is Arcutis Biotherapeutics Inc. a candidate for recovery playJuly 2025 Intraday Action & AI Powered Buy and Sell Recommendations - newser.com
What’s the recovery path for long term holders of Arcutis Biotherapeutics Inc.2025 Geopolitical Influence & Capital Protection Trading Alerts - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to global recession fearsJuly 2025 PreEarnings & Capital Efficient Trading Techniques - newser.com
Is Arcutis Biotherapeutics Inc. stock undervalued vs historical averagesMarket Performance Recap & Real-Time Volume Trigger Notifications - newser.com
Volatility clustering patterns for Arcutis Biotherapeutics Inc.Trade Exit Report & Advanced Swing Trade Entry Plans - newser.com
Arcutis Biotherapeutics CEO Watanabe sells $1m in shares By Investing.com - Investing.com Canada
Arcutis Biotherapeutics CEO Watanabe sells $1m in shares - Investing.com
Goldman Sachs Maintains Arcutis Biotherapeutics (ARQT) Neutral Recommendation - Nasdaq
Roflumilast Cream 0.05% Now Commercially Available for Pediatric Atopic Dermatitis - Dermatology Times
What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock - Yahoo Finance
Leading vs lagging indicators on Arcutis Biotherapeutics Inc. performanceJuly 2025 PostEarnings & Weekly Watchlist for Hot Stocks - newser.com
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments - The Manila Times
Tori Spelling Joins Arcutis Biotherapeutics in Launching Free to Be Me Campaign to Raise Awareness About Eczema and Seborrheic Dermatitis - Quiver Quantitative
Arcutis (NASDAQ: ARQT) joins Tori Spelling in 'Free to Be Me' for 36M patients - Stock Titan
Arcutis Biotherapeutics (ARQT) Launches ZORYVE Cream for Young C - GuruFocus
Arcutis Biotherapeutics launches new topical cream for children's eczema - Traders Union
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 - MarketScreener
Arcutis (NASDAQ: ARQT) launches ZORYVE 0.05% cream for children 2–5 with atopic dermatitis - Stock Titan
How Arcutis Biotherapeutics Inc. stock reacts to Fed rate cuts2025 Key Lessons & Daily Volume Surge Trade Alerts - newser.com
Multi asset correlation models including Arcutis Biotherapeutics Inc.Trade Performance Summary & Smart Swing Trading Techniques - newser.com
Will earnings trigger a reversal in Arcutis Biotherapeutics Inc.Market Weekly Review & AI Driven Price Predictions - newser.com
Arcutis Biotherapeutics, Inc. $ARQT Stake Lowered by Jennison Associates LLC - MarketBeat
Why hedge funds are buying Arcutis Biotherapeutics Inc. stockJuly 2025 Market Mood & High Return Trade Guides - newser.com
Will a bounce in Arcutis Biotherapeutics Inc. offer an exitJuly 2025 Weekly Recap & Fast Gain Stock Trading Tips - newser.com
Has Arcutis Biotherapeutics Inc. found a price floorMarket Volume Summary & Free Verified High Yield Trade Plans - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to inflationary pressures2025 Trade Ideas & Accurate Buy Signal Notifications - newser.com
Published on: 2025-10-30 01:04:15 - newser.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Given New $30.00 Price Target at Needham & Company LLC - MarketBeat
Arcutis Swings Into Profit As Skin Therapy Soars - Citeline News & Insights
Arcutis Biotherapeutics (NASDAQ:ARQT) Announces Quarterly Earnings Results, Beats Estimates By $0.15 EPS - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Reaches New 52-Week High After Better-Than-Expected Earnings - MarketBeat
Arcutis (ARQT) Soars to Record High on Swing to Profitability, ‘More-Than-Double’ Revenues - Insider Monkey
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2025 Earnings Call Transcript - Insider Monkey
Needham Maintains Arcutis Biotherapeutics (ARQT) Buy Recommendation - Nasdaq
Morgan Stanley Raises Price Target on Arcutis Biotherapeutics to $32 From $21, Keeps Overweight Rating - MarketScreener
Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates - sharewise.com
Arcutis Biotherapeutics stock hits 52-week high at $22.49 By Investing.com - Investing.com Australia
Decoding Arcutis Biotherapeutics Inc (ARQT): A Strategic SWOT Insight - GuruFocus
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):